BioSpace News Archive

Bio-Thera Solutions, Ltd. (SHA: 688177), a commercial-stage pharmaceutical company, today announced that dosing has begun in a Phase I clinical study to compare the pharmacokinetics and safety of BAT1308, a monoclonal antibody targeting PD-1 in cancer patient volunteers.

CorMedix Inc., a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, announced that it has been approved for listing on the Nasdaq Global Market.

Medexus Pharmaceuticals Inc. (the “ Company ” or “Medexus ”) (TSXV: MDP) (OTCQX: MEDXF) (Frankfurt: P731) announced today that it has submitted its application to list on The Nasdaq Capital Market® (the “ Nasdaq ”). Ken d’Entremont, Chief Executive Officer of Medexus, commented, “The submission of our application to list on the Nasdaq marks a significant milestone for Medexus.

Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that the Company will present at the MoneyShow Accredited Investors Virtual Expo taking place virtually January 26-28, 2021.

Merus N.V., a clinical-stage oncology company developing innovative, full-length multispecific antibodies, announced the pricing of an underwritten public offering of 4,848,485 common shares at a public offering price of $24.75 per share.

Thomas Scientific, the largest pure-play distributor of scientific products in the US, announced the launch of its Molecular Diagnostics business unit dedicated to serving the nation’s independent testing and reference laboratories.

Turn Therapeutics, a biotechnology company specializing in advanced wound care and infection control, today announced the initiation of a two-part, four-arm, human safety and efficacy trial for its flagship product, Hexagen, to be used in the fight against COVID-19.

FARE, the world’s leading non-governmental organization engaged in food allergy advocacy and the largest private funder of food allergy research, has awarded two competitive grants to partner institutions that will bolster FARE’s 2020 expansion of the FARE Clinical Network, powering advances in food allergy research.

Moderna Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the first participant has been dosed in the Phase 1/2 study of Moderna’s vaccine candidate against COVID-19 (mRNA-1273 or TAK-919) in Japan, led by Takeda Pharmaceutical Co., Ltd (NYSE: TAK). TAK-919 is Takeda’s development code for Moderna’s COVID-19 vaccine candidate.

Synaptogenix, Inc. (the “Company” or Synaptogenix) (OTCQX: SNPX), formerly Neurotrope Bioscience, Inc., announced today that it has entered into definitive securities purchase agreements with accredited investors to raise approximately $14.0 million in a private placement of common stock and warrants exercisable for common stock